| abstract |
The present disclosure relates, inter alia, to compositions containing human complement inhibitors and / or interferon alpha inhibitors, and the use of such compositions in methods for treating or preventing dogo disease in a subject. In some embodiments, the inhibitor is an antibody or antigen-binding fragment thereof that binds to a human complement component C5 protein, or a biologically active fragment of C5, such as C5a or C5b. In some embodiments, the inhibitor is an antibody or antigen-binding fragment thereof that binds to interferon alpha or an interferon alpha receptor. |